[{"data":1,"prerenderedAt":210},["ShallowReactive",2],{"drug-ipratropium":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":64,"warnings":84,"renal":85,"monitoring":86,"interactions":87,"review":88,"examples":91,"atc":98,"iran":100,"links":148,"populations":170,"usApproval":205},"ipratropium",1,{"fa":7,"en":8},"ایپراتروپیوم","Ipratropium bromide","respiratory",{"fa":11,"en":12},"آنتی‌کولینرژیک استنشاقی کوتاه‌اثر","Short-acting inhaled anticholinergic",[14],{"name":15,"market":16},"Atrovent HFA","US",[18,19,7,20],"atrovent","آتروونت","اسپری COPD",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"hfa-17","inhaler","inhaled","17 mcg per actuation (HFA)",{"amount":28,"unit":29,"perUnit":30},17,"mcg","actuation",[16],[33],{"source":34,"section":35},"fda-atrovent-hfa","3",[37],{"id":38,"disease":38,"label":39,"population":42,"type":46,"unit":29,"dose":47,"refs":50,"limits":53,"notes":57},"copd",{"fa":40,"en":41},"COPD (نگهدارنده) — ۲ پاف چهار بار در روز","COPD maintenance — 2 inhalations four times daily",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":48,"dosesPerDay":49},34,4,[51],{"source":34,"section":52},"2",{"maxPerDay":54,"refs":55},204,[56],{"source":34,"section":52},[58],{"text":59,"refs":62},{"fa":60,"en":61},"پاف اضافه در صورت نیاز؛ مجموع بیش از ۱۲ پاف در ۲۴ ساعت نشود. نیاز به تکان دادن ندارد.","Extra inhalations as required; total no more than 12 in 24 h. No shaking needed.",[63],{"source":34,"section":52},[65,74],{"id":66,"severity":67,"text":68,"refs":71},"ci","block",{"fa":69,"en":70},"حساسیت به ایپراتروپیوم، آتروپین یا مشتقات آن.","Hypersensitivity to ipratropium, atropine or its derivatives.",[72],{"source":34,"section":73},"4",{"id":75,"severity":67,"rule":76,"text":78,"refs":81},"child",{"maxAge":77},{"value":44,"unit":45},{"fa":79,"en":80},"در کودکان ثابت نشده.","Not established in children.",[82],{"source":34,"section":83},"8.4",[],[],[],[],{"status":89,"reviewer":90,"date":90},"unverified",null,[92],{"regimen":38,"formulation":23,"input":93,"expect":96},{"ageYears":94,"weightKg":95},65,70,{"perDose":48,"tabletsPerDoseRounded":97},2,[99],"R03BB01",{"status":101,"forms":102,"refs":143},"registered",[103,107,111,115,119,123,127,131,135,139],{"code":104,"en":105,"fa":106},"00708","IPRATROPIUM BROMIDE 20MCG\u002FDOSE SPRAY","اسپری ایپراتروپیوم بروماید ۲۰ میکروگرم \u002F دوز",{"code":108,"en":109,"fa":110},"19859","IPRATROPIUM BROMIDE 250MCG\u002F1ML SOL NEBULIZER","محلول ایپراتروپیوم بروماید ۲۵۰ میکروگرم \u002F ۱ میلی‌لیتر",{"code":112,"en":113,"fa":114},"11543","IPRATROPIUM BROMIDE 250MCG\u002F2ML SOL NEBULIZER","محلول ایپراتروپیوم بروماید ۲۵۰ میکروگرم \u002F ۲ میلی‌لیتر",{"code":116,"en":117,"fa":118},"01555","IPRATROPIUM BROMIDE 40MCG\u002FDOSE SPRAY","اسپری ایپراتروپیوم بروماید ۴۰ میکروگرم \u002F دوز",{"code":120,"en":121,"fa":122},"00709","IPRATROPIUM BROMIDE SOL FOR NEBULISATION","محلول ایپراتروپیوم بروماید نبولایزیشن",{"code":124,"en":125,"fa":126},"02148","IPRATROPIUM-S AEROSOL","ایپراتروپیوم–S",{"code":128,"en":129,"fa":130},"52199","IPRATROPIUM BROMIDE SOLUTION RESPIRATORY 250 ug\u002F1mL 20 mL","محلول ایپراتروپیوم بروماید ۲۵۰ میکروگرم \u002F ۱ میلی‌لیتر ۲۰ میلی‌لیتر",{"code":132,"en":133,"fa":134},"52033","IPRATROPIUM BROMIDE SPRAY, METERED NASAL 42 ug\u002F1{Puff}","فرآورده استنشاقی ایپراتروپیوم بروماید ۴۲ میکروگرم \u002F ۱ { }",{"code":136,"en":137,"fa":138},"52032","IPRATROPIUM BROMIDE SPRAY, METERED NASAL 21 ug\u002F1{Puff} 15 mL","فرآورده استنشاقی ایپراتروپیوم بروماید ۲۱ میکروگرم \u002F ۱ { } ۱۵ میلی‌لیتر",{"code":140,"en":141,"fa":142},"52663","IPRATROPIUM BROMIDE SPRAY, METERED NASAL 21 ug\u002F1{Puff} 25 mL","فرآورده استنشاقی ایپراتروپیوم بروماید ۲۱ میکروگرم \u002F ۱ { } ۲۵ میلی‌لیتر",[144],{"source":145,"section":146,"url":147},"darooyab-generic","G-1470\u002FIpratropium-Bromide","https:\u002F\u002Fwww.darooyab.ir\u002FG-1470\u002FIpratropium-Bromide",[149,153,157,161,164,167],{"kind":150,"url":151,"label":152},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021527","NDA021527",{"kind":154,"url":155,"label":156},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=170e98ef-5560-4068-be7d-e649068eb884","FDA Atrovent HFA",{"kind":158,"url":159,"label":160},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601063.html","Albuterol and Ipratropium Oral Inhalation",{"kind":158,"url":162,"label":163},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa618013.html","Ipratropium Nasal Spray",{"kind":165,"url":166,"label":99},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=R03BB01",{"kind":168,"url":147,"label":169},"darooyab","Ipratropium-Bromide",{"pregnancy":171,"lactation":180,"pediatric":189,"geriatric":197},{"level":172,"text":173,"quote":176,"refs":177},"ok",{"fa":174,"en":175},"برچسب: جذب سیستمیک ناچیز؛ مواجهه جنین انتظار نمی‌رود.","Label: minimal systemic absorption; fetal exposure not expected.","Risk Summary Ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [ see Clinical Pharmacology (12.3) ].",[178],{"source":34,"section":179},"8.1",{"level":181,"text":182,"quote":185,"refs":186},"caution",{"fa":183,"en":184},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of ipratropium in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.",[187],{"source":34,"section":188},"8.2",{"level":190,"text":191,"quote":194,"refs":195},"not-established",{"fa":192,"en":193},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in the pediatric population have not been established.",[196],{"source":34,"section":83},{"level":172,"text":198,"quote":201,"refs":202},{"fa":199,"en":200},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between these subjects and younger subjects.",[203],{"source":34,"section":204},"8.5",{"kind":206,"refs":207,"id":152},"NDA",[208],{"source":34,"section":209},"SPL approval \u002F marketing category",1792191880096]